Diabetic Gastroparesis Clinical Trial
Official title:
Scheme Optimization of Acupoints Compatibility and Influence Factors of the Effect
With Diabetic gastroparesis as the research object, by the method of multi-center RCT and single cavity and different acupuncture acupoints compatibility treatment of diabetic gastroparesis, the inspection of gastric emptying, gastric dynamic inspection, such as validity checking means, for single cavity with different acupoints compatibility evaluate clinical efficacy of treatment of diabetic gastroparesis.
Status | Recruiting |
Enrollment | 99 |
Est. completion date | August 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of Diabetic Gastroparesis; - Aged 18-60 (including 18 and 60); - Fasting venous blood sugar =7.8mmol/L,2-hour post-meal blood glucose = 13.6mmol/ L; - Diabetes more than 3 years; - Diet and exercise therapy or diet movement and exercise therapy based on the use of hypoglycemic drugs (except alpha glycosidase inhibitor) treatment, dose stable at least more than 3 months; - Rounding out the top three months did not participate in any clinical subjects; - Sign the informed consent and voluntary to participate in the study. Exclusion Criteria: - Patients with reflux esophagitis; - Postoperative gastroparesis patients; - Ketoacidosis, non ketosis acute complications such as hypertonic coma; - Patients with acute cardiovascular disease, with severe trauma or surgery, severe infections, pregnancy or breast-feeding women; - Patients with myocardial infa,acute coronary syndrome (ACS),coronary revascularization; - Patients with severe liver disease, or the AST and/or ALT 2 times higher than normal ceiling; - Patients with Serum creatinine kidney damage, more than 140 umol/L; - Patients with obvious blood system diseases (either in person are not to be included in the item: Hb: men < 110 g/L, women < 100 g/L, the WBC < 3.5×109/L/L, PLT < 80×109/L); - Patients's systolic pressure=180mmHg,Patients's diastolic pressure=100mmHg; - Patients with Advanced malignant tumor or other serious wasting disease, infection and bleeding; - Endoscopy has the organic lesion such as peptic ulcer; - Disorders or do not fit the person and the growing experiment condition or severe complications; - Nearly four weeks of alpha glycosidase inhibitor drugs. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | The Affiliated Hospital To Changchun University of Chinese Medicine | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Changchun University of Chinese Medicine | Hengyang Traditional Chinese Medicine Hospital, Jilin University, Qilu Hospital, Second People's Hospital of Hunan, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gastroparesis Symptoms Rating Scale(GCSI) | 8 weeks | No | |
Secondary | FBG(fasting blood-glucose) | 8 weeks | No | |
Secondary | PPG(postprandial blood sugar) | 8 weeks | No | |
Secondary | Gastric emptying check by Color ultrasonography | 8 weeks | No | |
Secondary | Gastric emptying check by X rays | 8 weeks | No | |
Secondary | Short form 36 health survey(SF-36) | 8 weeks | No | |
Secondary | Self-rating anxiety scale(SAS) | 1 week | No | |
Secondary | Self-Rating Depression Scale(SDS) | 1 week | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01557296 -
Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
|
Phase 2 | |
Withdrawn |
NCT03376399 -
Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
|
||
Not yet recruiting |
NCT02264587 -
Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis
|
Phase 4 | |
Completed |
NCT02289846 -
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
|
Phase 2 | |
Completed |
NCT03544229 -
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
|
Phase 2 | |
Recruiting |
NCT04706832 -
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
|
N/A | |
Not yet recruiting |
NCT05584462 -
Gastroparesis in type2 Diabetic Patient
|
||
Enrolling by invitation |
NCT05812339 -
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
|
||
Completed |
NCT02732821 -
G-POEM for Treatment of Refractory Gastroparesis
|
||
Completed |
NCT01030341 -
Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
|
N/A | |
Recruiting |
NCT05832151 -
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT02025725 -
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
|
Phase 3 | |
Completed |
NCT01916460 -
Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients
|
N/A | |
Completed |
NCT01469286 -
Transcutaneous Electroacupuncture for Gastroparesis
|
Phase 1 | |
Terminated |
NCT00874133 -
The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis
|
N/A | |
Completed |
NCT01126034 -
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
|
N/A | |
Recruiting |
NCT05273788 -
Thoracic Neuromodulation for Diabetic Gastroparesis
|
N/A | |
Suspended |
NCT00470795 -
Acupuncture for Diabetic Gastroparesis
|
Phase 3 | |
Completed |
NCT00139893 -
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
|
N/A | |
Recruiting |
NCT04254549 -
Rifaximin in Patients With Diabetic Gastroparesis
|
Phase 2 |